The largest malaria vaccine efficacy trial ever conducted in Africa
has proven that a candidate vaccine is safe in children aged 1 to 4 years
and can protect a significant proportion of them against uncomplicated malaria,
infection, and severe forms of the disease for at least 6 months.
“This is clearly the best result we’ve ever seen with a
candidate malaria vaccine,” said Pedro Alonso, MD, PhD, principal investigator
of the study and head of the Center for International Health of the Hospital
Clinic at the University of Barcelona, in Spain. “All the results point
in the same direction with great consistency and substantial precision. So
we’re quite certain not only that the vaccine has been safe and immunogenic
but that we’ve seen clear efficacy of this vaccine.”
Hampton T. Malaria Vaccine Shows Promise. JAMA. 2004;292(22):2703–2704. doi:10.1001/jama.292.22.2703
Customize your JAMA Network experience by selecting one or more topics from the list below.